Potent Name: Potent Name: Potent Potent	Kisunla™ (donanemab-azbt) Prescriber Order Form						
Primary Diagnosis Description: Cinical Information Cinical Information	Patient Name:		Date of Birth:				
Supporting documentation required for therapy: - Baseline brain MRI from within the past year. Subsequent brain MRI reports and written approval by the ordering prescriber must be obtained prior to the 2"0", 3", 4"), and 7" influsions. Kisunia" (donanemab-azbt) prescription	Address:						
Supporting documentation required for therapy: - Baseline brain MRI from within the past year. Subsequent brain MRI reports and written approval by the ordering prescriber must be obtained prior to the 2"", 3"", 4"", and 7" infusions. Sisunia" (donanemab-azbt) in 0.9% sodium chloride refill as directed x 1 year Initial Dose:	Phone:		_	inches 🗌 cm	Weight:	☐ Ibs ☐ kg	
Supporting documentation required for therapy: Baseline brain MRI from within the past year. Subsequent brain MRI reports and written approval by the ordering prescriber must be obtained prior to the 2 nd , 3 nd , 4 nd , and 7 nd infusions. Kisunla** (donanemab-azbt) in 0.9% sodium chloride refill as directed x 1 year	Primary Diagnosis Description	Clinical Info	ormation	ICD 10 Codo:			
Baseline brain MRI from within the past year. Subsequent brain MRI reports and written approval by the ordering prescriber must be obtained prior to the 2"d, 3"d, 4"d, and 7" infusions.	Primary Diagnosis Description.			icb-10 code.			
Normal saline 500mL (>30kg) or 1.55 mg (>30kg) or 2.50 mL (>30kg) or 2.50 mL (>30kg) or 3.00 mL (>30kg) or	Baseline brain MRI from within the past year. Subsequent brain MRI reports and written approval by the ordering prescriber must be						
Initial Dose:	Kisunla™ (donanemab-azbt) Prescription						
Anaphylaxis Kit If this is a 1st dose, would you like Option Care Health to provide an anaphylaxis kit with the 1st dose? Yes	Initial Dose: Infuse 700mg IV every 4 weeks for 3 infusions. Maintenance Dose: Infuse 1400 mg IV every 4 weeks. Medication will be infused over approximately 30 minutes with a 0.2 micron filter. Using a 50ml 0.9% Sodium Chloride IV bag, flush IV tubing with NS 10 to 20 mL after each infusion.						
If this is a 1st dose, would you like Option Care Health to provide an anaphylaxis kit with the 1st dose? Yes		Ancillary (Orders				
Certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment. Prescriber Signature:	If this is a 1 st dose, would you like Option Care Health to provide an anaphylaxis kit with the 1 st dose? Yes						
Prescriber Signature:	Refill above ancillary orders as directed x 1 year.						
Prescriber Information Prescriber Name: Address: City, State: Phone: Phone: Phone: Phone: Fax: Office Contact:	I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.						
Prescriber Name: Phone: Fax: Address: NPI: City, State: Zip: Office Contact:	-						
Address: NPI: City, State: Zip: Office Contact:	Duccaribou Name				Form		
City, State: Zip: Office Contact:					rdX:		

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners